Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]MK-6884 PET Biomarker Trial
NCT02621606Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of MK-6884 (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing an Adverse Event up to 15 days, Number of Participants Discontinuing the Study Due to an Adverse Event up to 15 days and 4 more. Started Jan 2016; status: completed.
02
Drugs
MK-6884
Beyond the preview
Go deeper on NCT02621606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621606.